316 related articles for article (PubMed ID: 37876939)
1. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic.
Rios-Hoyo A; Arriola E
Front Immunol; 2023; 14():1221097. PubMed ID: 37876939
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
3. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.
Yan X; Qu F; Zhou Y
Lung Cancer; 2023 Oct; 184():107322. PubMed ID: 37611495
[TBL] [Abstract][Full Text] [Related]
4. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
Wang Y; Chen R; Wa Y; Ding S; Yang Y; Liao J; Tong L; Xiao G
Front Immunol; 2022; 13():829451. PubMed ID: 35251014
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in NSCLC Patients with Brain Metastases.
Buriolla S; Pelizzari G; Corvaja C; Alberti M; Targato G; Bortolot M; Torresan S; Cortiula F; Fasola G; Follador A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806080
[TBL] [Abstract][Full Text] [Related]
6. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
9. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
12. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
Sheng J; Yu X; Li H; Fan Y
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
[TBL] [Abstract][Full Text] [Related]
16. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
Li W; Yu H
J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
Frega S; Bonanno L; Guarneri V; Conte P; Pasello G
Crit Rev Oncol Hematol; 2018 Aug; 128():19-29. PubMed ID: 29958628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]